专利检索 ap:("Pfizer Italia S.r.l.") AND inv:"TRIGG, William, John, Evotec OAI" 第 1 页

1.

发明授权
PYRROLO[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM 有权
标题翻译：吡咯并[2,3-B]吡啶衍生物作为激酶抑制剂WORK，METHOD FOR THEIR和药物组合物含

公开(公告)号：EP1701956B1

公开(公告)日：2010-02-24

申请号：EP04816308.3

申请日：2004-12-23

申请人： Pfizer Italia S.r.l.

发明人： SALOM, Barbara , D'ANELLO, Matteo , BRASCA, Maria, Gabriella , GIORDANO, Patrizia , MARTINA, Katia , ANGELUCCI, Francesco , BROOKFIELD, Frederick, Arthur , TRIGG, William, John, Evotec OAI , BOYD, Edward, Andrew , LARARD, Jonathan, Anthony

IPC分类号： C07D471/04 , A61K31/437

CPC分类号： C07D471/04

摘要： Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

2.

发明授权
PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM 有权
标题翻译：吡咯并[2,3-B]吡啶衍生物作为激酶抑制剂的行为; 这包括其制备方法及药物组合物，

公开(公告)号：EP1704147B1

公开(公告)日：2009-11-04

申请号：EP04804268.3

申请日：2004-12-23

申请人： Pfizer Italia S.r.l.

发明人： SALOM, Barbara , D'ANELLO, Matteo , BRASCA, Maria, Gabriella , GIORDANO, Patrizia , MARTINA, Katia , BROOKFIELD, Frederick, Arthur , TRIGG, William, John, Evotec OAI , BOYD, Edward, Andrew , LARARD, Jonathan, Anthony , TESEI, Dania

IPC分类号： C07D471/04 , A61K31/437 , A61P35/00

CPC分类号： C07D471/04

摘要： Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenrative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.